• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
XL-765

XL-765

Product ID X4424
Cas No. 934493-76-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $147.20 Please Inquire
5 mg $249.80 Please Inquire
10 mg $405.20 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

XL-765 is an inhibitor of PI3K and mTOR that displays anticancer chemotherapeutic and anti-angiogenic activities; it is currently in clinical trials as a potential treatment for lymphomas and solid tumors. XL-765 inhibits cell proliferation, tumor growth, and angiogenesis in cellular and animal models of cancers.

Product Info

Cas No.

934493-76-2

Purity

≥98%

Formula

C13H14N6O

Formula Wt.

270.29

IUPAC Name

2-Amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8H)-one

Synonym

XL765, Voxtalisib, SAR245409

Solubility

DMSO 12 mg/mL (20.01 mM) Water Insoluble Ethanol Insoluble

Appearance

Light yellow powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

X4424 MSDS PDF

Info Sheet

X4424 Info Sheet PDF

References

Papadopoulos KP, Egile C, Ruiz-Soto R, et al. Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. Leuk Lymphoma. 2014 Nov 19:1-8. [Epub ahead of print] PMID: 25300944.

Yu P, Laird AD, Du X, et al. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014 May;13(5):1078-91. PMID: 24634413.

Papadopoulos KP, Tabernero J, Markman B, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2014 May 1;20(9):2445-56. PMID: 24583798.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • K5606

    Kobe 2602

    Ras inhibitor.

    ≥98%
  • C5970

    Corydaline

    Alkaloid compound found in Corydalis.

    ≥94%
  • C8069

    Curcumin

    Diarylheptanoid found in Zingiberaceae.

    ≥97% curcuminoid content
  • P698579

    Propantheline Bromide

    Antimuscarinic

    ≥98%
  • A4002

    AK-7

    SIRT2 inhibitor.

    ≥98%
  • T286161

    Theaflavin

    Polyphenolic compound present in black tea.

    ≥98%
  • J023736

    (±)-Jasmonic Acid

    Phytohormone

    ≥98% (sum of isomers)
  • T5672

    Tosufloxacin Tosylate

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • S3033

    Shikimic Acid

    Cyclohexanecarboxylic acid found in various pla...

    ≥98%
  • J5237

    JNJ-26854165

    MDM2 inhibitor.

    ≥98%
  • C9809

    Cyclopiazonic Acid

    SERCA inhibitor.

    ≥98%, TLC
  • D1792

    Dextromethorphan Hydrobromide Hydrate

    σ1/2and μ/κ/δ-OR agonist, α3β4/α4β2/α7...

    ≥98%
  • R0161

    Rapamycin

    Macrolide originally produced by Streptomyces; ...

    ≥99%
  • A6800

    AR-A014418

    GSK-3β inhibitor.

    ≥98%
  • I2118

    Ifenprodil Hemitartrate

    NMDA NR1/NR2B antagonist.

    ≥98%
  • S7769

    Streptomycin Sulfate

    Aminoglycoside; protein translation inhibitor, ...

    ≥98%
  • C9708

    CYC-116

    AurKB/C inhibitor.

    ≥98%
  • R0020

    RAF265

    B-Raf, VEGFR2, c-Raf, PDGFR, CSF-1R, RET, c-Kit...

    ≥98%
  • G0104

    Gabexate Mesylate

    Proteasome inhibitor.

    ≥99%
  • U682040

    URB597

    FAAH inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only